Understanding how gut microbes affect epilepsy
Dissecting the role of gut microbial-derived metabolites on epilepsy
This study is looking at how the tiny microbes in your gut might affect seizures in people with epilepsy, hoping to find new ways to help those who don’t respond to current treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-10924042 on NIH RePORTER |
What this research studies
This research investigates the relationship between gut microbial metabolites and epilepsy, focusing on how these metabolites may influence seizure activity. By examining the gut-brain axis, the study aims to uncover specific mechanisms through which gut microbes can affect brain function and seizure outcomes. The research utilizes a viral model of epilepsy to explore these interactions, potentially leading to new therapeutic strategies for patients who are resistant to current treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults over 21 years old who suffer from epilepsy, particularly those who have not found relief with standard anti-epileptic drugs.
Not a fit: Patients with epilepsy caused by structural brain abnormalities or those who are not adults may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to novel treatments for epilepsy that target gut microbiota, offering hope for patients who do not respond to existing medications.
How similar studies have performed: While the gut-brain axis is a relatively novel area of investigation in epilepsy, preliminary studies have shown promising correlations between gut microbiota and seizure outcomes, suggesting potential for success in this approach.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Campbell, Susan Latoya — University of Alabama at Birmingham
- Study coordinator: Campbell, Susan Latoya
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.